Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Omnicom Group Inc. (OMC) Price & Performance

Cassava Sciences IncTrade
Omnicom Group Inc.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Omnicom Group Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Omnicom Group Inc. trades at $85.82 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 493.8× Cassava Sciences Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAOMC
Market Cap
$47.75M$23.58B
Sector
HealthMedia
52-Week High
$4.64$86.22
52-Week Low
$0.87$67.27
Enterprise Value
-$34.93M$31.66B
Dividend Yield
3.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Omnicom Group Inc.

Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.

Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Omnicom Group Inc.

Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.

Read more on OMC